GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pasithea Therapeutics Corp (NAS:KTTA) » Definitions » Price-to-Owner-Earnings

Pasithea Therapeutics (Pasithea Therapeutics) Price-to-Owner-Earnings : (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pasithea Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-24), Pasithea Therapeutics's share price is $6.40. Pasithea Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Pasithea Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:


KTTA's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.4
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-24), Pasithea Therapeutics's share price is $6.40. Pasithea Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-13.91. Therefore, Pasithea Therapeutics's PE Ratio for today is At Loss.

As of today (2024-05-24), Pasithea Therapeutics's share price is $6.40. Pasithea Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $-13.84. Therefore, Pasithea Therapeutics's PE Ratio without NRI for today is At Loss.


Pasithea Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Pasithea Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pasithea Therapeutics Price-to-Owner-Earnings Chart

Pasithea Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

Pasithea Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pasithea Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, Pasithea Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pasithea Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pasithea Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pasithea Therapeutics's Price-to-Owner-Earnings falls into.



Pasithea Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pasithea Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=6.40/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pasithea Therapeutics  (NAS:KTTA) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pasithea Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pasithea Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pasithea Therapeutics (Pasithea Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1111 Lincoln Road, Suite 500, Miami Beach, FL, USA, 33139
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses.
Executives
Graeme Martin Currie officer: Chief Development Officer 51 BARBAREE WAY, TIBURON CA 94920
Lawrence Steinman director 10555 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Bradford Manning 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Paul B Manning 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Tiger Lily Capital, Llc 10 percent owner C/O PBM CAPITAL GROUP, LLC, 200 GARRETT STREET, SUITE S, CHARLOTTESVILLE VA 22902
Pd Joint Holdings, Llc Series 2016-a 10 percent owner C/O TIGER LILY CAPITAL LLC, 200 GARRETT STREET, SUITE O, CHARLOTTESVILLE VA 22902
Elderhill Corp other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T IN5
Concord Ip2 Ltd. other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
David Delaney other: Member of 10% owner group C/O CONCORD INVESTMENT PARTNERS LTD., 60 ST. CLAIR AVENUE EAST, SUITE 702, TORONTO A6 M4T 1N5
Eric Shahinian other: Member of 10% owner group 350 PARK AVE, 13TH FL, NEW YORK NY 10022
Alfred J Novak director 325 NE 6TH ST, BOCA RATON FL 33432
Camac Partners, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Capital, Llc other: Member of 10% owner group 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Camac Fund, Lp other: Member of 10% owner group CAMAC CAPITAL, LLC, 350 PARK AVENUE, 13TH FLOOR, NEW YORK NY 10022
Leonite Capital Llc other: Member of 10% owner group 1 HILLCREST CENTER DR., SUITE 232, SPRING VALLEY NY 10977

Pasithea Therapeutics (Pasithea Therapeutics) Headlines

From GuruFocus